It's a mixed bag here. The roughly 30% growth in revenues from three quarters of the last fiscal year to three quarters of this fiscal year is OK, especially as the product mix shifts to higher margin products. But note that the company reported on net loss from operations, leaving out the negative impact of interest expenses. Meanwhile, let's see how many issued shares there will be reported as of March 31, 2016, as I'm just not sure what happened with the loan payoff due in April.
I'd believe that the delay in releasing the 10Q is likely all about how the footnote will read in regard to the FDA regulations. Given the action of the stock recently, I'd guess that the not-so-great financial results and the uncertain to negative regulatory environment have already been factored into the stock price, but it's really hard to keep an analytical frame of mind when the stock seems to bounce all over the place from trade to trade.
Overall, I think that this company is ripe for sale, as the products seem to be leading edge but the finances are holding the company back from fully capitalizing on its competitive advantages.
Maybe I'll add to this when the 10Q appears, but these are the moments when I miss folks like Sgreg on this board who are better at analysis than I am.
News 
Market Data 
Discover 
